MetaVia Updates Collaboration Progress with Syntekabio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4d ago
0mins
Should l Buy MTVA?
MetaVia provided an update on its ongoing collaboration with Syntekabio an AI-driven drug discovery company, leveraging their proprietary DeepMatcher platform. Using AI-based compound-protein interaction modeling, Syntekabio has identified key disease targets for MetaVia's oral G-protein-coupled receptor 119, or GPR119, agonist, vanoglipel, or DA-1241. The analysis highlighted inflammatory diseases, cardiometabolic disorders, and cancer as the top predicted target areas, directly aligning with MetaVia's therapeutic focus. Notably, cancer was identified, in part, due to the strong reduction in inflammation observed in AI-predicted target pathways. "The AI modeling results provide strong confirmation that vanoglipel engages key inflammatory targets, which supports our strategy in metabolic dysfunction-associated steatohepatitis and potential type 2 diabetes," stated Hyung Heon Kim, President and CEO of MetaVia. "Furthermore, the identification of inflammation, cardiometabolic, and cancer-related pathways reinforces that we are focused in the right therapeutic areas. MetaVia continues to advance DA-1241 for MASH and T2D, bolstered by our Phase 2a clinical study results which demonstrated direct hepatic activity, improvements in glucose metabolism, and a favorable safety and tolerability profile in 109 patients over 16 weeks. Together, these insights give us confidence in DA-1241's broader therapeutic potential."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MTVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MTVA
Wall Street analysts forecast MTVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MTVA is 47.50 USD with a low forecast of 40.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.730
Low
40.00
Averages
47.50
High
55.00
Current: 1.730
Low
40.00
Averages
47.50
High
55.00
About MTVA
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MetaVia Inc. Closes $9.3 Million Public Offering to Advance Obesity Treatment Development
- Funding Size: MetaVia Inc. has successfully closed a public offering raising approximately $9.3 million, which includes 3,005,574 shares of common stock and 4,508,361 Series C and D warrants, with proceeds aimed at advancing the clinical development of obesity treatment drug DA-1726, demonstrating the company's ongoing commitment to cardiometabolic diseases.
- Warrant Details: The Series C and D warrants were issued at a price of $3.10 per share, are immediately exercisable, with Series C warrants valid for five years and Series D for two years, potentially yielding up to $28 million in future proceeds if fully exercised, enhancing the company's financial flexibility.
- Underwriter Role: Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager for the offering, ensuring a smooth fundraising process and reflecting market confidence in MetaVia's future growth prospects.
- Clinical Trial Outlook: MetaVia is conducting a Phase 1b clinical trial for DA-1726, and positive data could trigger the call option for Series D warrants, further enhancing the company's competitive position in the obesity treatment market.
See More
MetaVia Inc. Closes $9.3 Million Public Offering to Advance Obesity Treatment Development
- Funding Amount: MetaVia Inc. has successfully closed a public offering raising approximately $9.3 million, which will be directed towards the clinical development of its obesity treatment drug DA-1726, demonstrating the company's ongoing commitment to cardiometabolic diseases.
- Shares and Warrants: The offering included 3,005,574 shares of common stock and 4,508,361 Series C and D warrants priced at $3.10 per share, indicating market confidence in its products and future potential.
- Future Revenue Potential: If the warrants are fully exercised, MetaVia could yield up to $28 million in future gross proceeds, providing substantial financial support for its research and operational needs.
- Underwriter Role: Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager for this offering, showcasing its expertise and influence in the biotechnology financing sector.
See More
MetaVia Inc. (MTVA) Prices $8.1 Million Public Offering, Shares Plunge 39%
- Public Offering Pricing: MetaVia Inc. announced an underwritten public offering priced at $3.10 per unit, aiming to raise approximately $8.1 million in gross proceeds before fees, with funds allocated for working capital and advancing its clinical pipeline.
- Significant Stock Decline: Following the announcement, MTVA shares plummeted by 39.03%, opening at $3.4050 after closing at $5.58 the previous day, indicating strong market reaction to the capital raise news.
- Surge in Trading Volume: The announcement triggered a spike in trading volume well above recent averages, reflecting heightened selling pressure and investor concerns regarding the company's future prospects, which may impact its ability to raise further capital.
- Increased Volatility: MetaVia's 52-week stock range of $3.10 to $25.20 highlights significant volatility associated with financing activities and clinical-stage biotech risks, potentially undermining investor confidence moving forward.
See More
MetaVia Prices $8.1M Public Offering with Series C and D Warrants
- Offering Size: MetaVia has priced its public offering to raise approximately $8.1 million, consisting of 2.61 million common shares and 3.92 million Series C and D warrants, indicating the company's proactive approach to financing.
- Warrant Details: The Series C warrants are immediately exercisable at $3.10 with a five-year expiration, while Series D warrants also priced at $3.10 expire in two years, potentially providing additional funding support for the company in the future.
- Use of Proceeds: The proceeds from this offering will be allocated towards working capital, corporate purposes, and the clinical development of DA-1726 obesity trials, highlighting the company's ongoing investment and strategic focus in R&D.
- Market Reaction: MetaVia's stock has dropped by 41.88%, reflecting market concerns regarding the offering and the company's overall financial health, which may impact investor confidence and future financing capabilities.
See More
Goldman Sachs Reports Q4 Earnings of $14.01 Per Share, Beating Estimates
- Goldman Sachs Earnings Highlight: The Goldman Sachs Group, Inc. (NYSE:GS) reported Q4 earnings of $14.01 per share, exceeding analyst expectations of $11.65, indicating strong profitability despite quarterly sales of $13.454 billion missing the $13.791 billion forecast, reflecting market demand fluctuations.
- Market Performance Recovery: The Dow Jones index rose approximately 200 points, up 0.41%, while the NASDAQ surged 0.78% and the S&P 500 gained 0.55%, indicating investor optimism about market prospects, particularly following Goldman Sachs' earnings report, which may further boost market confidence.
- Strong Tech Sector Performance: Information technology stocks gained 1.4% on Thursday, highlighting the sector's significance in the economic recovery and potentially attracting more investor attention towards the long-term growth potential of tech stocks.
- Initial Jobless Claims Decline: U.S. initial jobless claims fell by 9,000 to 198,000, below market expectations of 215,000, demonstrating labor market resilience that could support economic growth and further enhance investor confidence in the stock market.
See More
MetaVia Inc. Prices Public Offering, Raising $8.1 Million
- Offering Size: MetaVia Inc. announced the pricing of its public offering at $3.10 per share, issuing 2,613,544 shares and 3,920,316 Series C and D Warrants, aiming to raise approximately $8.1 million, indicating strong market engagement.
- Warrant Details: The Series C and D Warrants are immediately exercisable at $3.10, with the C Warrants expiring in five years and D Warrants in two years, enhancing investor participation and interest in the offering.
- Use of Proceeds: MetaVia intends to utilize the net proceeds from the offering for working capital and general corporate purposes, particularly to advance the clinical development of DA-1726 for obesity treatment, underscoring the company's commitment to R&D.
- Additional Purchase Option: The company granted underwriters a 45-day option to purchase an additional 392,030 shares and 588,045 Series C and D Warrants at the same offering price, further increasing market interest in the offering.
See More
MetaVia Inc. Closes $9.3 Million Public Offering to Advance Obesity Treatment Development
- Funding Size: MetaVia Inc. has successfully closed a public offering raising approximately $9.3 million, which includes 3,005,574 shares of common stock and 4,508,361 Series C and D warrants, with proceeds aimed at advancing the clinical development of obesity treatment drug DA-1726, demonstrating the company's ongoing commitment to cardiometabolic diseases.
- Warrant Details: The Series C and D warrants were issued at a price of $3.10 per share, are immediately exercisable, with Series C warrants valid for five years and Series D for two years, potentially yielding up to $28 million in future proceeds if fully exercised, enhancing the company's financial flexibility.
- Underwriter Role: Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager for the offering, ensuring a smooth fundraising process and reflecting market confidence in MetaVia's future growth prospects.
- Clinical Trial Outlook: MetaVia is conducting a Phase 1b clinical trial for DA-1726, and positive data could trigger the call option for Series D warrants, further enhancing the company's competitive position in the obesity treatment market.
See More
MetaVia Inc. Closes $9.3 Million Public Offering to Advance Obesity Treatment Development
- Funding Amount: MetaVia Inc. has successfully closed a public offering raising approximately $9.3 million, which will be directed towards the clinical development of its obesity treatment drug DA-1726, demonstrating the company's ongoing commitment to cardiometabolic diseases.
- Shares and Warrants: The offering included 3,005,574 shares of common stock and 4,508,361 Series C and D warrants priced at $3.10 per share, indicating market confidence in its products and future potential.
- Future Revenue Potential: If the warrants are fully exercised, MetaVia could yield up to $28 million in future gross proceeds, providing substantial financial support for its research and operational needs.
- Underwriter Role: Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager for this offering, showcasing its expertise and influence in the biotechnology financing sector.
See More
MetaVia Inc. (MTVA) Prices $8.1 Million Public Offering, Shares Plunge 39%
- Public Offering Pricing: MetaVia Inc. announced an underwritten public offering priced at $3.10 per unit, aiming to raise approximately $8.1 million in gross proceeds before fees, with funds allocated for working capital and advancing its clinical pipeline.
- Significant Stock Decline: Following the announcement, MTVA shares plummeted by 39.03%, opening at $3.4050 after closing at $5.58 the previous day, indicating strong market reaction to the capital raise news.
- Surge in Trading Volume: The announcement triggered a spike in trading volume well above recent averages, reflecting heightened selling pressure and investor concerns regarding the company's future prospects, which may impact its ability to raise further capital.
- Increased Volatility: MetaVia's 52-week stock range of $3.10 to $25.20 highlights significant volatility associated with financing activities and clinical-stage biotech risks, potentially undermining investor confidence moving forward.
See More
MetaVia Prices $8.1M Public Offering with Series C and D Warrants
- Offering Size: MetaVia has priced its public offering to raise approximately $8.1 million, consisting of 2.61 million common shares and 3.92 million Series C and D warrants, indicating the company's proactive approach to financing.
- Warrant Details: The Series C warrants are immediately exercisable at $3.10 with a five-year expiration, while Series D warrants also priced at $3.10 expire in two years, potentially providing additional funding support for the company in the future.
- Use of Proceeds: The proceeds from this offering will be allocated towards working capital, corporate purposes, and the clinical development of DA-1726 obesity trials, highlighting the company's ongoing investment and strategic focus in R&D.
- Market Reaction: MetaVia's stock has dropped by 41.88%, reflecting market concerns regarding the offering and the company's overall financial health, which may impact investor confidence and future financing capabilities.
See More
Goldman Sachs Reports Q4 Earnings of $14.01 Per Share, Beating Estimates
- Goldman Sachs Earnings Highlight: The Goldman Sachs Group, Inc. (NYSE:GS) reported Q4 earnings of $14.01 per share, exceeding analyst expectations of $11.65, indicating strong profitability despite quarterly sales of $13.454 billion missing the $13.791 billion forecast, reflecting market demand fluctuations.
- Market Performance Recovery: The Dow Jones index rose approximately 200 points, up 0.41%, while the NASDAQ surged 0.78% and the S&P 500 gained 0.55%, indicating investor optimism about market prospects, particularly following Goldman Sachs' earnings report, which may further boost market confidence.
- Strong Tech Sector Performance: Information technology stocks gained 1.4% on Thursday, highlighting the sector's significance in the economic recovery and potentially attracting more investor attention towards the long-term growth potential of tech stocks.
- Initial Jobless Claims Decline: U.S. initial jobless claims fell by 9,000 to 198,000, below market expectations of 215,000, demonstrating labor market resilience that could support economic growth and further enhance investor confidence in the stock market.
See More
MetaVia Inc. Prices Public Offering, Raising $8.1 Million
- Offering Size: MetaVia Inc. announced the pricing of its public offering at $3.10 per share, issuing 2,613,544 shares and 3,920,316 Series C and D Warrants, aiming to raise approximately $8.1 million, indicating strong market engagement.
- Warrant Details: The Series C and D Warrants are immediately exercisable at $3.10, with the C Warrants expiring in five years and D Warrants in two years, enhancing investor participation and interest in the offering.
- Use of Proceeds: MetaVia intends to utilize the net proceeds from the offering for working capital and general corporate purposes, particularly to advance the clinical development of DA-1726 for obesity treatment, underscoring the company's commitment to R&D.
- Additional Purchase Option: The company granted underwriters a 45-day option to purchase an additional 392,030 shares and 588,045 Series C and D Warrants at the same offering price, further increasing market interest in the offering.
See More
